Tuhura Biosciences

Tuhura Biosciences Developing Novel Technologies to Overcome Resistance to Cancer Immunotherapy.

TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update https://bit.ly/3Ru...
04/01/2025

TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

https://bit.ly/3RupHZD

Phase 3 IFx-2.0 accelerated approval trial as adjunctive therapy with Keytruda® (pembrolizumab) in 1st line therapy for advanced Merkel cell carcinoma (MCC) planning to initiate enrollment in Q2 2025

We are leveraging our technology platform to develop next-generation candidates and expand into blood-related cancers. ...
03/24/2025

We are leveraging our technology platform to develop next-generation candidates and expand into blood-related cancers.

Be the first to know when we post new updates. Stay informed by signing up here:https://bit.ly/3t5Ayks
03/18/2025

Be the first to know when we post new updates. Stay informed by signing up here:
https://bit.ly/3t5Ayks

Dr. Tendler believes TuHURA's innovative portfolio has the potential to impact immuno-oncology and is excited to contrib...
03/13/2025

Dr. Tendler believes TuHURA's innovative portfolio has the potential to impact immuno-oncology and is excited to contribute his oncology drug development expertise to the Board and management for the company's growth and success.

https://bit.ly/3FlO49a

We’ll be at the 37th Annual Roth Conference, March 16th-18th, 2025, in Dana Point, CA! Looking forward to connecting wit...
03/12/2025

We’ll be at the 37th Annual Roth Conference, March 16th-18th, 2025, in Dana Point, CA! Looking forward to connecting with everyone there!

https://bit.ly/3FrJTIO

James Bianco, CEO of TuHURA, shares his excitement in welcoming Dr. Craig Tendler to the Board of Directors. He highligh...
03/12/2025

James Bianco, CEO of TuHURA, shares his excitement in welcoming Dr. Craig Tendler to the Board of Directors. He highlights Dr. Tendler's expertise in oncology development to support TuHURA’s Phase 3 trial and cancer immunotherapy pipeline.

https://bit.ly/3FlO49a

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostic...
03/11/2025

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors

https://bit.ly/3FlO49a

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference
03/11/2025

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference


TAMPA, FL / ACCESS Newswire / March 10, 2025 / TuHURA Biosciences, Inc. (NASDAQ:HURA) (“TuHURA”), a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that James A. Bianco, M.D., President and Chief Exe...

While checkpoint inhibitors have revolutionized cancer treatment, overcoming tumor resistance is still a key challenge t...
03/10/2025

While checkpoint inhibitors have revolutionized cancer treatment, overcoming tumor resistance is still a key challenge to improving patient outcomes. Learn how we are working to address this issue: https://bit.ly/47ShQvv

Although is ending, the fight to continues. Support research by joining the American Association for Cancer Research...
02/27/2025

Although is ending, the fight to continues. Support research by joining the American Association for Cancer Research in making a difference. Learn more here: https://bit.ly/3G9ZFmv

Address

Tampa, FL
33612

Website

Alerts

Be the first to know and let us send you an email when Tuhura Biosciences posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category